摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(3-Methoxypropyl)morpholine | 82057-89-4

中文名称
——
中文别名
——
英文名称
4-(3-Methoxypropyl)morpholine
英文别名
——
4-(3-Methoxypropyl)morpholine化学式
CAS
82057-89-4
化学式
C8H17NO2
mdl
——
分子量
159.23
InChiKey
KNZJMAOIFHKXEK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    11
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    21.7
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • [EN] COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS<br/>[FR] COMPOSÉS POUR INHIBER LA PROLIFÉRATION CELLULAIRE DANS LES CANCERS INDUITS PAR L'EGFR
    申请人:ARIAD PHARMA INC
    公开号:WO2013169401A1
    公开(公告)日:2013-11-14
    The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula (I), wherein the variables are as defined herein.
    这项发明涉及化合物、药物组合物和治疗EGFR驱动的Formula (I)癌症患者的方法,其中变量如本文所定义。
  • [EN] DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS<br/>[FR] DÉRIVÉS DE DIAZABICYCLO[4.3.1]DÉCANE POUR LE TRAITEMENT DE TROUBLES PSYCHIATRIQUES
    申请人:MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V
    公开号:WO2015110271A1
    公开(公告)日:2015-07-30
    The present invention relates to diazabicyclo[4.3.1 ]decane derivatives (I), pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives are specific inhibitors of the FK506 binding proteins (FKBP's) and can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
    本发明涉及二氮杂双环[4.3.1]癸烷生物(I),这些化合物的药用盐以及含有至少一种这些化合物的药用载体、赋形剂和/或稀释剂的药物组合物。所述的二氮杂双环[4.3.1]癸烷生物是FK506结合蛋白(FKBP)的特异性抑制剂,可用于预防和/或治疗精神障碍和神经退行性疾病、障碍和症状。
  • Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders
    申请人:Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    公开号:EP2899192A1
    公开(公告)日:2015-07-29
    The present invention relates to diazabicyclo[4.3.1]decane derivatives of formula (I), pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives are inhibitors of the FK506 binding protein (FKBP's) and can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
    本发明涉及式(I)的二氮杂双环[4.3.1]癸烷生物,这些化合物的药用盐以及含有至少一种这些化合物的药用载体、赋形剂和/或稀释剂的药物组合物。所述的二氮杂双环[4.3.1]癸烷生物是FK506结合蛋白(FKBP's)的抑制剂,可用于预防和/或治疗精神障碍和神经退行性疾病、障碍和症状。
  • DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS
    申请人:MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    公开号:US20170002003A1
    公开(公告)日:2017-01-05
    The present invention relates to diazabicyclo[4.3.1]decane derivatives, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
    本发明涉及二氮杂双环[4.3.1]癸烷生物,这些化合物的药用盐以及含有至少一种这些化合物的药用载体、赋形剂和/或稀释剂的药物组合物。所述的二氮杂双环[4.3.1]癸烷生物可用于预防和/或治疗精神障碍和神经退行性疾病、障碍和症状。
  • NOVEL COMPOUNDS
    申请人:GRAUERT Matthias
    公开号:US20130184248A1
    公开(公告)日:2013-07-18
    This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R 1 , R 2 , R 3 have meanings given in the description.
    这项发明涉及到式I的化合物,它们作为mGlu5受体活性的正向变构调节剂的用途,含有这些化合物的药物组合物,以及将其用作治疗和/或预防与谷酸功能障碍相关的神经和精神疾病,如精神分裂症或认知功能下降,如痴呆症或认知障碍的药剂的方法。A、B、Ar、R1、R2、R3在描述中有给定的含义。
查看更多